| Metric | Q2-26 | Q2-25 |
|---|---|---|
| Revenue | 357.76 | 327.31 |
| Gross Profit | 220.91 | 194.74 |
| Pretax Income | 62.86 | 51.28 |
| Net Income | 46.30 | 38.68 |
| Diluted EPS | 1.00 | 0.81 |
- Net Income YoY
- +19.7%
Key highlights
- Net revenue grew 9.3% year-over-year to $357.76 million
- Net income rose to $46.30 million, up from $38.68 million in the prior-year quarter
- Diluted earnings per share increased to $1.00 from $0.81
- Gross profit climbed to $220.91 million, representing significant margin expansion
- Pretax income improved to $62.86 million compared to $51.28 million previously
How the Period Went
Haemonetics Corporation recorded a 9.3% increase in net revenue, reaching $357.76 million for the quarter ended September 26, 2026, compared to $327.31 million in the prior-year period. This top-line expansion translated into stronger profitability, as net income surged by 19.7% to $46.30 million. Diluted earnings per share followed this upward trajectory, rising from $0.81 to $1.00. Growth was primarily underpinned by higher gross profits and the absence of intangible asset impairments that had impacted the bottom line during the second quarter of fiscal 2025. The result marks a sequential improvement over the $339.38 million in revenue reported in the preceding quarter.
Margins and Profitability
Gross profit for the quarter rose to $220.91 million, a substantial improvement over the $194.74 million reported in the same period last year. This performance indicates a gross margin of approximately 61.7%, up from 59.5% year-over-year. Pretax income also demonstrated resilience, climbing to $62.86 million from $51.28 million. The margin expansion reflects a shift toward higher-margin products and operational efficiencies within the medical devices segment. Furthermore, the exclusion of one-time impairment costs, which weighed on previous results, bolstered the operating profile, allowing the company to convert a higher percentage of revenue into net earnings.
Business Overview
- Core operations focus on blood management and hospital-based medical devices
- Key segments include Plasma, Blood Center, and Hospital solutions
- The Plasma segment is currently undergoing a nationwide U.S. transition of CSL Plasma centers to NexSys PCS devices
- The company serves global end markets including blood collection centers and surgical suites
- Transition of CSL Plasma centers to advanced technologies is targeted for completion by December 31, 2027
Financial Context
The Q2 2026 performance sits within a period of significant stock price appreciation, with Haemonetics shares rising 46.81% over the last quarter. This momentum has pushed the company's market capitalization to approximately $5.80 billion. With a price-to-earnings ratio of 61.56, the company is trading at a premium compared to many historical benchmarks. Technical indicators show a Relative Strength Index (RSI) of 75.2, suggesting the stock is currently in overbought territory. The steady revenue growth from $327.31 million to $357.76 million reflects the company's ability to maintain upward momentum as it cycles through major technology rollouts in its plasma division.
Down 4.8% since our story on 5 Nov: $127.42 when we broke it → $121.34 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $118.73 |
|---|---|
| 20 Oct | $118.21 |
| 21 Oct | $117.11 |
| 22 Oct | $116.16 |
| 23 Oct | $118.51 |
| 26 Oct | $119.19 |
| 27 Oct | $119.97 |
| 28 Oct | $118.32 |
| 29 Oct | $119.79 |
| 30 Oct | $119.65 |
| 2 Nov | $120.14 |
| 3 Nov | $120.28 |
| 4 Nov | $127.42 |
| 5 Nov | $124.11 |
| 6 Nov | $119.93 |
| 9 Nov | $118.21 |
| 10 Nov | $122.36 |
| 11 Nov | $120.54 |
| 12 Nov | $122.71 |
| 13 Nov | $122.94 |
| 16 Nov | $121.34 |
Industry Landscape
The medical device sector is experiencing a period of transformation as healthcare providers prioritize automated systems to improve procedural yields and mitigate labor constraints. Haemonetics operates in a competitive environment alongside firms like Terumo and Baxter, where success is increasingly tied to long-term hardware placement contracts and recurring software-enabled revenue. Demand for plasma-derived therapies continues to drive volume in the collection space, supporting the adoption of proprietary systems like the NexSys PCS. As the industry stabilizes following post-pandemic supply chain disruptions, focus has shifted toward operational efficiency and the integration of digital data management in blood collection workflows.
| Date | Announcement | Amount |
|---|---|---|
| 06 Aug 2026 | Q1 FY2027 net revenue and raised FY2027 guidanceSource: SEC filing | $339.4 Million |
| 07 May 2026 | Q4 FY2026 net revenue and FY2027 guidanceSource: haemonetics.gcs-web.com | $346.4 Million |
| 05 Feb 2026 | Q3 FY2026 net revenue and raised FY2026 guidanceSource: SEC filing | $339.0 Million |
| 06 Nov 2025 | Q2 FY2026 net revenue and raised FY2026 guidanceSource: haemonetics.gcs-web.com | $327.3 Million |
| 07 Aug 2025 | Q1 FY2026 net revenue and reaffirmed FY2026 guidanceSource: haemonetics.gcs-web.com | $321.4 Million |
| 08 May 2025 | Q4 FY2025 net revenue and FY2026 guidanceSource: haemonetics.gcs-web.com | $330.6 Million |
| Share price | $127.42 |
|---|---|
| Market cap | $5.8B |
| Revenue (annual) | $1.3B |
| P/E (TTM) | 61.6× |
| 1-month price change | +21.72% |
| Sector | HealthcareMedical Devices |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Haemonetics Corporation announcing financial results for the quarter ended September 26, 2026.
Track HAEMONETICS CORP live
Get the next HAEMONETICS CORP SEC filing seconds after it lands.



